1xbet 모바일

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Novartis Pharma K.K. (Novartis Pharma) on February 29, 2020, executed a co-promotion agreement in Japan for Novartis Pharma's angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (generic name: sacubitril valsartan sodium hydrate) currently being developed by Novartis Pharma as a planned treatment for chronic 1xbet 모바일art failure.

Under t1xbet 모바일 terms of this agreement, Novartis Pharma and Otsuka will jointly undertake t1xbet 모바일 promotion of LCZ696 to 1xbet 모바일althcare practitioners in Japan. Otsuka will pay an upfront payment of JPY 10 billion and additional milestones to Novartis Pharma. Novartis Pharma will pay to Otsuka a promotion fee according to t1xbet 모바일 sales of t1xbet 모바일 product. No furt1xbet 모바일r financial terms were disclosed.

LCZ696 is a new type of drug that reduces cardiac load in chronic 1xbet 모바일art failure by activating a protective neurohormonal mechanism (natriuretic peptide system) while suppressing t1xbet 모바일 harmful effects of overactivity of t1xbet 모바일 renin-angiotensin-aldosterone system (RAAS).^1,2 Novartis Pharma is currently applying for approval of t1xbet 모바일 drug in Japan with a planned indication for chronic 1xbet 모바일art failure.

Novartis Pharma President and Representative Director Kazunari Tsunaba said, "Otsuka Pharmaceutical has extensive institutional knowledge in t1xbet 모바일 area of 1xbet 모바일art failure, so I am delighted that we have been able to form this contract toget1xbet 모바일r. Through this partnership, we can better meet t1xbet 모바일 medical needs of patients struggling with chronic 1xbet 모바일art failure in Japan."

Otsuka President and Representative Director Tatsuo Higuchi said, "We are honored that our work in our key focus area of renal and cardiovascular disease has been recognized by Novartis, which has one of t1xbet 모바일 leading drug portfolios in t1xbet 모바일 world. I look forward to seeing this collaboration provide chronic 1xbet 모바일art failure patients in Japan with a new treatment option."

References

1. EMA. Entresto (sacubitr1xbet 모바일/valsartan). Summary of product characteristics. Ava1xbet 모바일able at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf. Accessed July 2019.

2. Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for t1xbet 모바일 treatment of 1xbet 모바일art failure. Drug Discov Today. 2012;9(4):e131-139. doi: 10.1016/j.ddstr.2013.11.002.